Does Intra-Operative Methylprednisolone Improve Outcomes of Surgery for Degenerative Cervical Myelopathy? - A Prospective Randomized Study
Open Access
- 13 December 2024
- journal article
- research article
- Published by SAGE Publications in Global Spine Journal
- Vol. 15 (5) , 2687-2698
Abstract
Study design: Randomized controlled trial. Objectives: In this study, we hypothesize administering fixed-dose intravenous steroid (Methylprednisolone) intraoperatively would reduce neuroinflammation and enhance functional and radiological outcomes in decompressive surgeries for DCM. Primary objectives were to assess effect of intraoperative MP on modified Japanese Orthopedic Association (mJOA) score, Nurick grade, and MRI signal changes. Methods: This prospective triple-blinded randomized controlled trial included 65 patients allocated into MP (n = 33) and control (n = 32) groups. MP (dose-1g) was administered intraoperatively at the beginning of decompression. Clinical outcome measures included mJOA score, Nurick grading, mJOA recovery rate (mJOA RR), Nurick recovery rate (NRR), and complication rates in both groups at 1-, 3-and 24-month follow-up. Radiological outcome was assessed by analyzing regression of T2W and T1W SI changes on MRI scans as per Chen’s grading at 24-months follow-up. Results: MP group exhibited greater improvement in mJOA scores at 24-months (mean improvement: +6.69 vs +6.42; difference: +0.27, 95% CI: −0.37 to +0.91) but was statistically insignificant ( P = .107). Similarly, mJOA-RR showed a moderate effect size of 0.42 (95% CI: 0.04 to 0.80) and 0.37 (95% CI: −0.01 to 0.75) at 1-and 3-months follow-up respectively. NRR improvements were observed, with effect sizes of 0.40 (95% CI: 0.02 to 0.78) and 0.49 (95% CI: 0.11 to 0.87) at 1- and 3-months respectively, but not statistically significant ( P = .28). At 24-months, MP group had significantly better MRI outcome (Chen grading: mean change +1.15 vs +0.83; effect size: −0.71, 95% CI: −1.09 to −0.33; P = .038).Complication rates were comparable between both groups, emphasizing safety of MP administration. Conclusion: Although null hypothesis was not proven, intraoperative MP administration in DCM surgery demonstrated safety and suggested potential neuroprotective benefits to enhance clinical recovery and reduce spinal cord signal changes. However, further large-scale, multicentric studies are needed to validate these findings and optimize its dose.Keywords
This publication has 38 references indexed in Scilit:
- Cochrane Review on the Role of Surgery in Cervical Spondylotic RadiculomyelopathySpine, 2002
- Intramedullary High Signal Intensity on T2-Weighted MR Images in Cervical Spondylotic Myelopathy: Prediction of Prognosis with Type of IntensityRadiology, 2001
- Cervical Spondylotic Myelopathy: Diagnosis and TreatmentJournal of the American Academy of Orthopaedic Surgeons, 2001
- A Review of the Pathophysiology of Cervical Spondylotic Myelopathy With Insights for Potential Novel Mechanisms Drawn From Traumatic Spinal Cord InjurySpine, 1998
- Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study.1997
- Effect of methylprednisolone on the cytokine response in patients undergoing lung surgeryActa Anaesthesiologica Scandinavica, 1993
- Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-year follow-up dataJournal of Neurosurgery, 1992
- A Randomized, Controlled Trial of Methylprednisolone or Naloxone in the Treatment of Acute Spinal-Cord InjuryNew England Journal of Medicine, 1990
- Interleukin-1 induces interleukin-6 production in peripheral blood monocytesBlood, 1990
- Methylprednisolone and neurological function 1 year after spinal cord injuryJournal of Neurosurgery, 1985